Araris Biotech AG, of Zurich, Switzerland, said it closed an oversubscribed seed financing round of CHF2.5 million (US$2.55 million) with participation by Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of antibody-drug conjugates.